Tissue-agnostic target profiles and treatment efficacy in cancer patients: Insights from the C-CAT clinicogenomic repository
- 25 March 2025
- journal article
- Published by Elsevier in European Journal of Cancer
- Vol. 220, 115380
Abstract
No abstract availableKeywords
Funding Information
- National Cancer Center
This publication has 47 references indexed in Scilit:
- Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 studyAnnals of Oncology, 2022
- Phase 2 Study of Dabrafenib Plus Trametinib in Patients With BRAF V600E-Mutant Metastatic NSCLC: Updated 5-Year Survival Rates and Genomic AnalysisJournal of Thoracic Oncology, 2022
- Cancer in adolescents and young adults in Japan: epidemiology and cancer strategyInternational Journal of Clinical Oncology, 2021
- LBA15 Primary outcome of the phase III SYD985.002/TULIP trial comparing [vic-]trastuzumab duocarmazine to physician’s choice treatment in patients with pre-treated HER2-positive locally advanced or metastatic breast cancerAnnals of Oncology, 2021
- 271P First-in-human, phase I dose escalation and expansion study of anti-HER2 ADC MRG002 in patients with HER2 positive solid tumorsAnnals of Oncology, 2021
- Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 studyThe Lancet Oncology, 2020
- Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trialsThe Lancet Oncology, 2020
- Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trialsThe Lancet Oncology, 2020
- Long‐term effects of crizotinib in ALK‐positive tumors (excluding NSCLC): A phase 1b open‐label studyAmerican Journal of Hematology, 2018
- Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trialThe Lancet Oncology, 2015